| WestConn scholarship honors Dr. Mel |
|
|
| Written by Jeff Bailey | |
| Tuesday, 25 September 2007 | |
|
The Danbury News Times gave Dr. Mel and the scholarship in his name a nice write-up this past Sunday. Here's a bit of what Robert Miller wrote:
For 26 years, Goldstein was the head of the meteorology department at Western Connecticut State University in Danbury. But to say he was the head is an understatement. In fact, he created it. |
| < Prev | Next > |
|---|
Multiple Myeloma News Update
-
Research forum Sept. 16 to focus on multiple myeloma
UConn Advance, CT - 2 hours ago
... research forum focusing on issues related to contemporary clinical and investigative approaches to multiple myeloma will take place on Tuesday, Sept. ... -

Network MédicaBiogen Idec and Elan Corp Announce Start of Trials with Tysabri as ...
Network Médica, Argentina - 2 hours ago
The treatments for multiple myeloma are led by biotech Celgene, with several drugs on the market: Revlimid, with sales for $ 613 million dollars in the ... -

Network MédicaBiogen to test Tysabri as a cancer treatment
Bizjournals.com, NC - 4 hours ago
Eligible candidates must have multiple myeloma and have failed with previous treatments. Biogen Idec makes Tysabri at a manufacturing plant in Research ...
Biogen’s battered MS drug in cancer treatment trials Mass High Tech
Elan and Biogen Idec Initiate First Clinical Trial of TYSABRI® in ... elEconomista.es
Tysabri clinical study underway Hays Pharma
Pharma Times (subscription)all 37 news articles -
Bortezomib plus melphalan-prednisone improved response rate in ...
HemOncToday, NJ - 9 hours ago
Melphalan and prednisone plus bortezomib may improve time to progression in patients with newly diagnosed multiple myeloma. According to researchers from ... -
Elan, Biogen Idec commence first clinical trial of Tysabri in ...
RTT News, NY - 15 hours ago
Patients with eighteen years and above suffering from relapsed or refractory multiple myeloma and those who failed or cannot tolerate therapy with ... -
Elan, Biogen launch Tysabri trial in oncology
Reuters - 16 hours ago
The first dose was administered on Thursday, they said. Multiple myeloma is a cancer of the plasma cell. (Reporting by Jonathan Saul; Editing by Quentin Bryar) -
Human Genome Sciences reports initial results from Phase II ...
Pharmaceutical Business Review - 21 hours ago
By Staff Writer The initial data from the multiple myeloma study show that HGS-ETR1 was well tolerated and suggest that disease response was comparable for ... -
Human Genome Sciences Reports Initial Results Of Randomized Phase ...
Medical News Today (press release), UK - Sep 4, 2008
The initial data from the multiple myeloma study show that HGS-ETR1 was well tolerated and suggest that disease response was comparable for this combination ...












